• Ionis Pharmaceuticals has reported second-quarter 2026 results showing revenue of US$268 million and a net loss of US$115 million, while also announcing the planned February 2027 retirement of founding scientist and chief scientific officer Frank Bennett, Ph.D., who will remain as a strategic consultant during the transition.
• Despite the loss, the quarter featured revenue and earnings surpassing analyst expectations and highlighted advancing RNA-targeted programs, including the launch of TRYNGOLZA and regulatory reviews for zilganersen in Alexander disease and bepirovirsen for chronic hepatitis B.
• We’ll now examine how the stronger-than-expected quarter and TRYNGOLZA launch progress influence Ionis Pharmaceuticals’ existing investment narrative and risk profile.

The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Ionis Pharmaceuticals Investment Narrative Recap

To own Ionis Pharmaceuticals, you need to believe its RNA-targeted platform can convert late-stage programs and new launches like TRYNGOLZA into durable, expanding revenue, despite current losses. The latest quarter, with revenue of US$268 million and a net loss of US$115 million, broadly supports that thesis but does not materially change the near term focus on upcoming FDA decisions for assets like zilganersen and bepirovirsen, or the key risk around pricing and launch execution.

Among recent updates, the Priority Review of zilganersen for Alexander disease stands out here, because it reinforces Ionis’ dependence on a small set of late stage approvals to justify rising R&D and commercialization spend. As with the TRYNGOLZA launch, the outcome and eventual uptake of zilganersen will feed directly into whether Ionis’ current loss making profile can move toward the earnings power some analysts expect over the next few years.

Yet behind the strong pipeline story, investors should be aware that pricing pressure across FCS, sHTG and newer indications could...

Ionis Pharmaceuticals’ narrative projects $2.2 billion revenue and $212.1 million earnings by 2029.

Uncover how Ionis Pharmaceuticals' forecasts yield a $92.00 fair value, a 66% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were assuming Ionis could reach about US$2.8 billion in revenue and US$456.4 million in earnings by 2029, but after a quarter where revenue beat expectations while losses widened and key approvals still carry clinical and regulatory risk, you can see how views on pricing pressure and launch outcomes might shift, so it is worth comparing these bullish assumptions with more cautious scenarios for yourself.

Explore 3 other fair value estimates on Ionis Pharmaceuticals - why the stock might be worth just $79.71!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Ionis Pharmaceuticals research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Ionis Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ionis Pharmaceuticals' overall financial health at a glance.

No Opportunity In Ionis Pharmaceuticals?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Find 49 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.